Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.
Shanghai Argo Biopharmaceutical Co. unveiled a pair of license and collaboration deals on 7 January with Novartis AG, both centered on discovery and development of next-generation RNAi therapeutics. Novartis is paying $185m up front under the two agreements, which could bring Argo an estimated $4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?